Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Codiak Biosciences Inc (CDAK)

Codiak Biosciences Inc (CDAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Codiak BioSciences Reports Second Quarter 2022 Financial Results and Operational Progress Globe Newswire - Thu Aug 4, 2022

– Reported platform-validating initial data from Phase 1 studies of exoSTING™ and exoIL-12™; plans to initiate Phase 2 studies for both programs in 1H 2023...

CDAK : 0.0570 (-55.98%)
Codiak BioSciences to Participate in Upcoming BTIG and Wedbush PacGrow Investor Conferences Globe Newswire - Wed Aug 3, 2022

CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the...

CDAK : 0.0570 (-55.98%)
Codiak BioSciences to Participate at William Blair Biotech Focus Conference 2022 Globe Newswire - Mon Jul 11, 2022

CAMBRIDGE, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the...

CDAK : 0.0570 (-55.98%)
CEPI and Codiak BioSciences partner to develop broadly protective Betacoronavirus vaccine Globe Newswire - Tue Jul 5, 2022

OSLO, Norway and CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- CEPI, the Coalition for Epidemic Preparedness Innovations, and Codiak BioSciences...

CDAK : 0.0570 (-55.98%)
Codiak Provides Platform-Validating Clinical Update and Data from Phase 1 Trials of exoSTING™ and exoIL-12™ Globe Newswire - Thu Jun 30, 2022

– Codiak’s engineered exosome candidates demonstrate potential for best-in-class profile, with tumor retention and delivery to the cells of interest...

CDAK : 0.0570 (-55.98%)
Codiak BioSciences Reports First Quarter 2022 Financial Results and Operational Progress Globe Newswire - Thu May 5, 2022

– Codiak to provide data from ongoing exoSTING™ and exoIL-12™ clinical trials in late 1H 2022 – – Anticipate first patients dosed in exoASO™-STAT6 Phase 1...

CDAK : 0.0570 (-55.98%)

Barchart Exclusives

As Palantir Lands a Deal With Cleveland-Cliffs, Should You Buy, Sell, or Hold PLTR stock? Barchart - 13 minutes ago
Palantir is landing deals with the likes of Cleveland-Cliffs, the USDA, and Stellantis as its revenue surges. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.